A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-06
Target enrollment:
Participant gender:
Summary
A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients with Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (UDCA).